The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Androgen Deprivation Therapy for Prostate Cancer
Abstract
CONTEXT: Prostate cancer is the most common nonskin cancer and second most common cause of cancer mortality in US men. Androgen deprivation therapy (ADT), specifically surgical or medical castration, is the first line of treatment against advanced prostate cancer and is also used as an adjuvant to local treatment of high-risk disease. OBJECTIVE: To review systematically the evidence on the risks and benefits of ADT for prostate cancer as well as clinical management of its adverse effects. EVIDENCE ACQUISITION: We performed MEDLINE searches of English-language literature (1966 to March 2005) using the terms androgen deprivation therapy, hormone treatment, and prostate cancer. We reviewed bibliographies of literature to extract other relevant articles. Studies were selected based on clinical pertinence, with an emphasis on controlled study design. EVIDENCE SYNTHESIS: Androgen deprivation therapy is effective for palliation in many patients with advanced prostate cancer and improves outcomes for high-risk patients treated with radiation therapy for localized disease. Although patients with increasing prostate-specific antigen levels after local treatment without metastatic disease frequently undergo ADT, the benefits of this strategy are not clear. Adverse effects of ADT include decreased libido, impotence, hot flashes, osteopenia with increased fracture risk, metabolic alterations, and changes in cognition and mood. CONCLUSIONS: Androgen deprivation therapy has clear roles in the management of advanced prostate cancer and high-risk localized disease. The benefits of ADT in other settings need to be weighed carefully against substantial risks and adverse effects on quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Huggins, C., & Hodges, C. V. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,855
Natural History of Progression After PSA Elevation Following Radical Prostatectomy
Pound, C. R. (1999) · JAMA · doi:10.1001/jama.281.17.1591 · Cited by 3,071
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09408-4 · Cited by 1,686
Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., & Chen, B. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1458 · Cited by 1,656
Bolla, M., Gonzalez, D., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., Gil, T., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707313370502 · Cited by 1,548
HUGGINS, C. (1941) · Archives of Surgery · doi:10.1001/archsurg.1941.01210140043004 · Cited by 1,499
A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210702 · Cited by 1,464
Risk of Fracture after Androgen Deprivation for Prostate Cancer
Shahinian, V. B., Kuo, Y.-F., Freeman, J. L., & Goodwin, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041943 · Cited by 1,375
Messing, E. M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E. D., & Trump, D. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912093412401 · Cited by 1,191
Bubley, G. J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M., Figg, W. D., Freidlin, B., Halabi, S., Hudes, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3461 · Cited by 977
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D., Miller, G., McLeod, D. G., Loehrer, P. J., Wilding, G., Sears, K., Culkin, D. J., Thompson, I. M., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391504 · Cited by 859
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials
(2000) · The Lancet · doi:10.1016/s0140-6736(00)02163-2 · Cited by 819
D'Amico, A. V., Manola, J., Loffredo, M., Renshaw, A. A., DellaCroce, A., & Kantoff, P. W. (2004) · JAMA · doi:10.1001/jama.292.7.821 · Cited by 767
Changes in body composition during androgen deprivation therapy for prostate cancer
Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8299 · Cited by 697
Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer
Smith, M. R., McGovern, F. J., Zietman, A. L., Fallon, M. A., Hayden, D. L., Schoenfeld, D. A., Kantoff, P. W., & Finkelstein, J. S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010845 · Cited by 696
(1997) · British Journal of Urology · doi:10.1046/j.1464-410x.1997.d01-6840.x · Cited by 654
SMITH, M. R., EASTHAM, J., GLEASON, D. M., SHASHA, D., TCHEKMEDYIAN, S., & ZINNER, N. (2003) · Journal of Urology · doi:10.1097/01.ju.0000063820.94994.95 · Cited by 650
Pilepich, M. V., Caplan, R., Byhardt, R. W., Lawton, C. A., Gallagher, M. J., Mesic, J. B., Hanks, G. E., Coughlin, C. T., Porter, A., Shipley, W. U., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.1013 · Cited by 607
Byar, D. P. (1973) · Cancer · doi:10.1002/1097-0142(197311)32:5<1126::aid-cncr2820320518>3.0.co;2-c · Cited by 597
Adib, R., Anderson, J., Ashken, M. H., Baumber, C. D., CRA, B. D., BEYNON, L. L., Blaxland, J. W., Boag, V., Bolger, J., Boreham, J., et al. (1997) · Kent Academic Repository (University of Kent) · Cited by 551
Megestrol acetate for the prevention of hot flashes.
Loprinzi, C. L., Michalak, J. C., Quella, S. K., O'Fallon, J. R., Hatfield, A. K., Nelimark, R. A., Dose, A. M., Fischer, T., Johnson, C., Klatt, N. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408113310602 · Cited by 500
Lawton, C. A., Winter, K., Murray, K., Machtay, M., Mesic, J. B., Hanks, G. E., Coughlin, C. T., & Pilepich, M. V. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)01516-9 · Cited by 374
Tolis, G., Ackman, D., Stellos, A., Mehta, A., Labrie, F., Fazekas, A. T., Comaru-Schally, A. M., & Schally, A. V. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.5.1658 · Cited by 368
BERRUTI, A., DOGLIOTTI, L., TERRONE, C., CERUTTI, S., ISAIA, G., TARABUZZI, R., REIMONDO, G., MARI, M., ARDISSONE, P., DE LUCA, S., et al. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64985-3 · Cited by 315
Oefelein, M. G., Feng, A., Scolieri, M. J., Ricchiutti, D., & Resnick, M. I. (2000) · Urology · doi:10.1016/s0090-4295(00)00793-7 · Cited by 279
Diamond, T. H., Higano, C. S., Smith, M. R., Guise, T. A., & Singer, F. R. (2004) · Cancer · doi:10.1002/cncr.20056 · Cited by 255
Potosky, A. L., Knopf, K., Clegg, L. X., Albertsen, P. C., Stanford, J. L., Hamilton, A. S., Gilliland, F. D., Eley, J. W., Stephenson, R. A., & Hoffman, R. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.17.3750 · Cited by 251
HERR, H. W., & O’SULLIVAN, M. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67533-7 · Cited by 250
Green, H. J., Pakenham, K. I., Headley, B. C., Yaxley, J., Nicol, D. L., Mactaggart, P. N., Swanson, C., Watson, R. B., & Gardiner, R. A. (2002) · BJU International · doi:10.1046/j.1464-410x.2002.02917.x · Cited by 239
STRUM, S. B., McDERMED, J. E., SCHOLZ, M. C., JOHNSON, H., & TISMAN, G. (1997) · British Journal of Urology · doi:10.1046/j.1464-410x.1997.00234.x · Cited by 215
Kuhn, J.-M., Billebaud, T., Navratil, H., Moulonguet, A., Fiet, J., Grise, P., Louis, J.-F., Costa, P., Husson, J.-M., Dahan, R., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210701 · Cited by 209
Loblaw, D. A., Mendelson, D. S., Talcott, J. A., Virgo, K. S., Somerfield, M. R., Ben-Josef, E., Middleton, R., Porterfield, H., Sharp, S. A., Smith, T. J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.579 · Cited by 191
Lawton, C. A., Winter, K. A., Grignon, D. J., & Pilepich, M. V. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.141 · Cited by 161
Hormonal therapy: historical perspective to future directions
McLeod, D. G. (2003) · Urology · doi:10.1016/s0090-4295(02)02393-2 · Cited by 155
Depression in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: A Pilot Study
Pirl, W. F., Siegel, G. I., Goode, M. J., & Smith, M. R. (2002) · Psycho-Oncology · doi:10.1002/pon.592 · Cited by 149 · cited 1×
“However, this was not associated with ADT.(57) Other Changes.”
BackgroundQuella, S. K., Loprinzi, C. L., Sloan, J. A., Novotny, P. J., Perez, E. A., Burch, P. A., Antolak, S. J., & Pisansky, T. M. (1999) · The Journal of Urology · doi:10.1097/00005392-199907000-00024 · Cited by 143
Dawson, N. A., & McLeod, D. G. (1995) · The Journal of Urology · doi:10.1016/s0022-5347(01)67365-8 · Cited by 122
LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action
Limonta, P., Marelli, M. M., & Moretti, R. M. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.4.709 · Cited by 112
Fowler, F. J., COLLINS, M. M., Corkery, E. W., Elliott, D. B., & Barry, M. J. (2002) · Cancer · doi:10.1002/cncr.10656 · Cited by 110
Walsh, P. C., DeWeese, T. L., & Eisenberger, M. A. (2001) · The Journal of Urology · doi:10.1016/s0022-5347(05)65972-1 · Cited by 110
Androgen deprivation and cognition in prostate cancer
Salminen, E. K., Portin, R. I., Korpela, J., Bäckman, H., Parvinen, L.-M., Helenius, H. Y. M., & Nurmi, M. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601235 · Cited by 100
Complications of androgen deprivation therapy for prostate cancer
Holzbeierlein, J. M., McLaughlin, M. D., & Thrasher, J. B. (2004) · Current Opinion in Urology · doi:10.1097/00042307-200405000-00007 · Cited by 93
The Influence of Androgen Deprivation Therapy on Metabolism in Patients with Prostate Cancer
Nishiyama, T., Ishizaki, F., Anraku, T., Shimura, H., & Takahashi, K. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1611 · Cited by 91
Gynecomastia in patients with prostate cancer: a review of treatment options
McLeod, D. G., & Iversen, P. (2000) · Urology · doi:10.1016/s0090-4295(00)00823-2 · Cited by 82
Pilot Evaluation of Paroxetine for Treating Hot Flashes in Men
Loprinzi, C. L., Barton, D. L., Carpenter, L. A., Sloan, J. A., Novotny, P. J., Gettman, M. T., & Christensen, B. J. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.10.1247 · Cited by 75
Higano, C. S. (2004) · Urologic Clinics of North America · doi:10.1016/j.ucl.2004.01.001 · Cited by 72
Estradiol and cognition during androgen deprivation in men with prostate carcinoma
Salminen, E. K., Portin, R. I., Koskinen, A., Helenius, H. Y. M., & Nurmi, M. (2005) · Cancer · doi:10.1002/cncr.20962 · Cited by 70
Secondary hormonal therapies in the treatment of prostate cancer
Oh, W. K. (2002) · Urology · doi:10.1016/s0090-4295(02)01581-9 · Cited by 63
Trump, D. L. (2004) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2004.07.010 · Cited by 62
Sartor, O. A., & Eastham, J. A. (1999) · Southern Medical Journal · doi:10.1097/00007611-199904000-00013 · Cited by 57
Complications of androgen deprivation therapy in men with prostate cancer
Chen, A. C., & Petrylak, D. P. (2004) · Current Oncology Reports · doi:10.1007/s11912-004-0051-0 · Cited by 34
Changes in Body Composition During Hormonal Therapy for Prostate Cancer
Smith, M. R. (2003) · Clinical Prostate Cancer · doi:10.3816/cgc.2003.n.008 · Cited by 26
Early versus late hormonal therapy: debating the issues
Crawford, E. D. (2003) · Urology · doi:10.1016/s0090-4295(02)02394-4 · Cited by 11
Cited by
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455
Denosumab in men receiving androgen-deprivation therapy for prostate cancer
Smith, M. R., Egerdie, B., Toriz, N. H., Feldman, R., Tammela, T. L. J., Saad, F., Heracek, J., Szwedowski, M., Ke, C., Kupic, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809003 · Cited by 1,140
Smith, M. R., Saad, F., Coleman, R., Shore, N., Fizazi, K., Tombal, B., Miller, K., Sieber, P., Karsh, L., Damião, R., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61226-9 · Cited by 797
Galvão, D. A., Taaffe, D. R., Spry, N., Joseph, D., & Newton, R. U. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2488 · Cited by 657
Stahlhut, R. W., van Wijngaarden, E., Dye, T. D., Cook, S., & Swan, S. H. (2007) · Environmental Health Perspectives · doi:10.1289/ehp.9882 · Cited by 646
Metadata
- Authors
- Sharifi, N.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2005-07-13
- Volume
- 294
- Issue
- 2
- Pages
- 238
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2161282696
- Cited by
- 1,083
- References
- 54
- FWCI
- 35.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.